JP2018525994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525994A5 JP2018525994A5 JP2018510109A JP2018510109A JP2018525994A5 JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5 JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018510109 A JP2018510109 A JP 2018510109A JP 2018525994 A5 JP2018525994 A5 JP 2018525994A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- sample
- splice variants
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074145A JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562212876P | 2015-09-01 | 2015-09-01 | |
| US62/212,876 | 2015-09-01 | ||
| PCT/US2016/049490 WO2017040526A2 (en) | 2015-09-01 | 2016-08-30 | Splice variants associated with neomorphic sf3b1 mutants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074145A Division JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525994A JP2018525994A (ja) | 2018-09-13 |
| JP2018525994A5 true JP2018525994A5 (https=) | 2019-10-10 |
| JP6876680B2 JP6876680B2 (ja) | 2021-05-26 |
Family
ID=56936518
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510109A Active JP6876680B2 (ja) | 2015-09-01 | 2016-08-30 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
| JP2021074145A Active JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074145A Active JP7256840B2 (ja) | 2015-09-01 | 2021-04-26 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10889866B2 (https=) |
| EP (2) | EP3344780B1 (https=) |
| JP (2) | JP6876680B2 (https=) |
| ES (1) | ES2887201T3 (https=) |
| WO (1) | WO2017040526A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6876680B2 (ja) | 2015-09-01 | 2021-05-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
| CA3056389A1 (en) * | 2017-03-15 | 2018-09-20 | Eisai R&D Management Co., Ltd. | Spliceosome mutations and uses thereof |
| US12098172B2 (en) | 2017-07-31 | 2024-09-24 | The Johns Hopkins University | Compositions and methods for targeting MASAs to treat cancers with spliceosome mutations |
| SG11202009906TA (en) * | 2018-04-09 | 2020-11-27 | Eisai R&D Man Co Ltd | Pladienolide compounds and their use |
| CN119405832A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| EP3801523B1 (en) * | 2018-06-01 | 2024-09-11 | Eisai R&D Management Co., Ltd. | Splicing modulators |
| IL262658A (en) * | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
| JP6931860B2 (ja) * | 2019-02-08 | 2021-09-08 | 株式会社Ｚｅｎｉｃｋ | ｍＲＮＡ前駆体の解析方法、情報処理装置、コンピュータプログラム |
| WO2020162613A1 (ja) * | 2019-02-08 | 2020-08-13 | 株式会社Ｚｅｎｉｃｋ | ｍＲＮＡ前駆体の解析方法、情報処理装置、コンピュータプログラム |
| US20230159920A1 (en) * | 2019-06-26 | 2023-05-25 | Fred Hutchinson Cancer Research Center | Methods and compositions comprising brd9 activating therapies for treating cancers and related disorders |
| CN111518805A (zh) * | 2020-04-30 | 2020-08-11 | 北京航空航天大学 | 一种可用于抑制肿瘤增殖的非编码基因及其应用 |
| ES2891182A1 (es) * | 2020-07-14 | 2022-01-26 | Servicio Andaluz De Salud | Compuestos para el tratamiento del carcinoma hepatocelular |
| US20240043928A1 (en) | 2020-11-04 | 2024-02-08 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| CN116507334A (zh) * | 2020-11-04 | 2023-07-28 | 卫材R&D管理有限公司 | 骨髓增生异常综合征（mds）的生物标记物及其使用方法 |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023209074A1 (en) * | 2022-04-28 | 2023-11-02 | Institut National de la Santé et de la Recherche Médicale | Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372431B1 (en) * | 1999-11-19 | 2002-04-16 | Incyte Genomics, Inc. | Mammalian toxicological response markers |
| ES2263589T3 (es) | 2000-02-18 | 2006-12-16 | Centelion | Procedimiento para aplicar polialquileniminas funcionalizadas, composiciones que las contienen y sus aplicaciones. |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
| US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| CA2494536C (en) | 2002-07-31 | 2011-10-04 | Mercian Corporation | A 12-membered ring macrolide active substance |
| JP4459051B2 (ja) | 2002-07-31 | 2010-04-28 | メルシャン株式会社 | 新規生理活性物質 |
| BR0316746A (pt) | 2002-11-29 | 2005-10-18 | Mercian Corp | Método de produção do composto macrolida 11107d, linhagem streptomyces sp.ab-1704 (ferm bp-8551), linhagem mortierella sp. f1529 (ferm bp-8547) ou linhagem f-1530 (ferm bp-8548), e linhagem ab-1896 (ferm bp-8550) |
| CN1886505A (zh) | 2003-11-27 | 2006-12-27 | 美露香株式会社 | 参与大环内酯类化合物的羟化作用的dna |
| US8008049B2 (en) | 2004-07-20 | 2011-08-30 | Eisai R&D Management Co., Ltd. | DNA coding for polypeptide participating in biosynthesis of pladienolide |
| JPWO2007043621A1 (ja) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | プラジエノライドｂ及びプラジエノライドｄの全合成方法 |
| WO2008111464A1 (ja) * | 2007-03-05 | 2008-09-18 | Eisai R & D Management Co., Ltd. | スプライシング異常を指標とする抗ガン剤の作用検定方法 |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| US8519115B2 (en) | 2008-08-14 | 2013-08-27 | Nanostring Technologies, Inc. | Stable nanoreporters |
| WO2011129427A1 (ja) * | 2010-04-16 | 2011-10-20 | 第一三共株式会社 | 癌の診断剤および治療剤 |
| SG10202010758SA (en) | 2011-11-08 | 2020-11-27 | Genomic Health Inc | Method of predicting breast cancer prognosis |
| WO2013086464A1 (en) * | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
| JP6057408B2 (ja) | 2012-03-05 | 2017-01-11 | 国立大学法人 千葉大学 | 癌の予防剤および／または治療剤 |
| US20140275010A1 (en) | 2013-03-12 | 2014-09-18 | Guo Zhu Zheng | Quaternary salts |
| WO2014165753A1 (en) | 2013-04-05 | 2014-10-09 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for diagnosis of glioblastoma or a subtype thereof |
| LT3143016T (lt) | 2014-05-15 | 2019-06-10 | Eisai R&D Management Co., Ltd. | Pladienolido piridino junginiai ir panaudojimo būdai |
| JP6876680B2 (ja) | 2015-09-01 | 2021-05-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント |
-
2016
- 2016-08-30 JP JP2018510109A patent/JP6876680B2/ja active Active
- 2016-08-30 ES ES16766420T patent/ES2887201T3/es active Active
- 2016-08-30 WO PCT/US2016/049490 patent/WO2017040526A2/en not_active Ceased
- 2016-08-30 EP EP16766420.0A patent/EP3344780B1/en active Active
- 2016-08-30 US US15/755,225 patent/US10889866B2/en active Active
- 2016-08-30 EP EP21174658.1A patent/EP3910073B1/en active Active
-
2020
- 2020-11-16 US US17/098,940 patent/US11761045B2/en active Active
-
2021
- 2021-04-26 JP JP2021074145A patent/JP7256840B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525994A5 (https=) | ||
| Eyles et al. | Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma | |
| Northcott et al. | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma | |
| Serrano et al. | Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas | |
| Riveiro-Falkenbach et al. | Intra-and inter-tumoral homogeneity of BRAFV600E mutations in melanoma tumors | |
| JP2017512491A5 (https=) | ||
| JP2015210268A5 (https=) | ||
| JP2019510066A5 (https=) | ||
| Bobba et al. | Scar carcinoma of the lung: a historical perspective | |
| Zoghlami et al. | BRAF mutation in papillary thyroid carcinoma: predictive value for long-term prognosis and radioiodine sensitivity | |
| Seedor et al. | Genetic landscape and emerging therapies in uveal melanoma | |
| RU2018145532A (ru) | Композиции и способы диагностирования раковых заболеваний легких с помощью профилей экспрессии генов | |
| Matsuura et al. | CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma | |
| Chen et al. | BRAF mutation may have different prognostic implications in early-and late-stage colorectal cancer | |
| Bohn et al. | BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation | |
| Kotelevets et al. | The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression | |
| Dela Cruz et al. | A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma | |
| US20190256920A1 (en) | Differential Identification of Pancreatic Cysts | |
| Dimitrakopoulos et al. | Variant of BCL3 gene is strongly associated with five-year survival of non-small-cell lung cancer patients | |
| Jelovac et al. | The amplification of c-erb-B2 in cancer-free surgical margins is a predictor of poor outcome in oral squamous cell carcinoma | |
| KR20150132206A (ko) | 예측성 바이오마커에 대한 검정법 | |
| EP4419668A1 (en) | Use of nanopore sequencing for determining the origin of circulating dna | |
| Calabria et al. | The new challenge in oncology: Next-generation sequencing and its application in precision medicine | |
| Han et al. | Homotypic interaction of stabilin-2 plays a critical role in lymph node metastasis of tongue cancer | |
| JP6860148B2 (ja) | 治療法の有利性を予見する予見方法 |